Hyatt Regency Orlando
Florida C, Convention Level
9801 International Dr
Orlando, FL 32819
6:30 PM: Registration and Dinner
7:00 PM: Welcome and Introduction
7:05 PM: Recognizing, Diagnosing, and Managing MCC: What Do Academic and Community-Based Providers Need to Know?
7:25 PM: Immunotherapy 101: The Rationale and Options for Targeting the Highly Immunogenic MCC With Anti−PD-1/PD-L1 Agents and Other Novel Immune-Based Therapies
7:45 PM: Emerging Evidence on Immune Checkpoint Blockade Therapy in MCC: Latest Data and Implications for Clinical Practice
8:05 PM: Future Directions in Immunotherapy for MCC and Beyond: Where Are We Now and Where Are We Going?
8:25 PM: Reflections and Conclusions
Anti-cancer immunotherapy is showing remarkable promise in Merkel cell carcinoma (MCC) and is expected to become the new backbone of therapy for patients with these aggressive skin cancers who previously had very limited treatment options. In this Progress-in-Practice Master Class, experts will discuss the key etiologic factors, oncogenic mechanisms, and immunogenicity of MCC, as well as data from clinical trials assessing immune-based treatment approaches and practicalities related to their use in MCC. The current state of the science and future research directions related to biomarkers, novel immune targets, and various combination strategies in MCC and beyond—including other virus-associated cancers—will also be explored.
Upon completion of this activity, participants will be able to:
This activity is intended for medical oncologists, dermatologists, skin cancer specialists, surgeons, nurses, and other healthcare professionals engaged in the care of patients with MCC.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test and evaluation form.
Release and Expiration Date: February 24, 2017
Time to Complete: 90 minutes
Prof. Jürgen C. Becker, MD, PhD
Translational Skin Cancer Research
German Consortium for Translational Cancer Research - DKTK
University Hospital Essen
Biological Faculty (coop)
Sunandana Chandra, MD, MS
Division of Hematology Oncology
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Geoffrey T. Gibney, MD
Melanoma Disease Group
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
Guilherme Rabinowits, MD
Medical Oncology Instructor in Medicine
Harvard Medical School
Dana-Farber Cancer Institute Center for Head and Neck Oncology
Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education
This activity has been planned and implemented by Rutgers Biomedical and Health Sciences and PVI, PeerView Institute for Medical Education. Rutgers Biomedical and Health Sciences is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.
Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is awarded 1.5 contact hours.
This CME/CNE activity is jointly provided by Rutgers Biomedical and Health Sciences and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Pfizer and EMD Serono.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.